Health-Related Outcomes in Patients Who Were Previously Treated for Rhabdomyosarcoma

NCT00003801 | Completed

• 4 other identifiers: CDR0000066945IRS-D9801CCG-D9801POG-D9801
• Study Type: interventional
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

RATIONALE: Cancer treatment may have risks that affect health outcomes later. It is not yet known what health outcomes may be related to previous treatment for rhabdomyosarcoma. PURPOSE: Study to determine health outcomes in patients who have survived 5 years after receiving treatment for rhabdomyosarcoma on the Intergroup Rhabdomyosarcoma Study Group protocols.

Conditions

Long-term Effects Secondary to Cancer Therapy in Children; Sarcoma

Keywords

long-term effects secondary to cancer therapy in children; previously treated childhood rhabdomyosarcoma

Interventions

management of therapy complications PROCEDURE

quality-of-life assessment PROCEDURE

Eligibility Criteria

• Age: 5 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

DISEASE CHARACTERISTICS: Prior registration on Intergroup Rhabdomyosarcoma Study Group Study IRS-I, IRS-II, IRS-III, IRS-IV pilot, IRS-V, or IRS-V pilot, or one of the protocols of IRS-V (D9501, D9502, D9602) AND Survived for 5 years after diagnosis (may be deceased now) PATIENT CHARACTERISTICS: Age: 5 and over Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified PRIOR CONCURRENT THERAPY: See Disease Characteristics

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• National Cancer Institute (NCI): lead
• Pediatric Oncology Group: collaborator
• Children's Cancer Group: collaborator

MeSH Terms

Conditions

Sarcoma

Condition Hierarchy (Ancestors)

Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms

Study Officials

• William M. Crist, MD

  University of Missouri-Columbia

  STUDY CHAIR

• Michael P. Link, MD

  Stanford University

  STUDY CHAIR

• R. Beverly Raney, MD

  M.D. Anderson Cancer Center

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: not applicable
• Purpose: SUPPORTIVE CARE
• Sponsor Type: NIH

Study Record Dates

• First Submitted: November 1, 1999
• First Posted: May 20, 2004
• Last Updated: August 20, 2009

Record last verified: 2000-02